Is ABIOMED, Inc. (ABMD) A Stock To Be Permanently Long On?

ABIOMED, Inc. (NASDAQ:ABMD) is on recovery track with 61.97% gain from a 1-year low price of $219.13. The company added 4.02% to attain the price of $354.92 on 02/11/2019. Throughout the recent session, the prices were hovering between $342.55 and $356.3. These shares are 23.01% off its target price of $436.6 and the current market capitalization stands at $16.02B. The recent change has given its price a 9.27% lead over SMA 50 and -22.8% deficit over its 52-week high. The stock witnessed 5.91% gains, -13.88% declines and -6.78% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ABMD’s volatility during a week at 3.16% and during a month it has been found around 3.85%.

ABIOMED, Inc. (ABMD) Top Holders

Institutional investors currently hold around $13.61 billion or 91.6% in ABMD stock. Look at its top three institutional owners. Vanguard Group Inc owns $1.59 billion in ABIOMED, Inc., which represents roughly 9.9% of the company’s market cap and approximately 11.65% of the institutional ownership. Similar statistics are true for the second largest owner, Primecap Management Co/Ca/, which owns 3,371,940 shares of the stock are valued at $1.15 billion. The third largest holder is Blackrock Inc., which currently holds $1.08 billion worth of this stock and that ownership represents nearly 6.74% of its market capitalization.

ABIOMED, Inc. 13F Filings

At the end of September reporting period, 246 institutional holders increased their position in ABIOMED, Inc. (NASDAQ:ABMD) by some 4,835,237 shares, 262 decreased positions by 4,620,504 and 81 held positions by 30,438,121. That puts total institutional holdings at 39,893,862 shares, according to SEC filings. The stock grabbed 68 new institutional investments totaling 1,059,741 shares while 73 institutional investors sold out their entire positions totaling 490,265 shares.

ABIOMED, Inc. (NASDAQ:ABMD) Insider Trades

Multiple company employees have indulged in significant insider trading. ABIOMED, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Sutter Martin P has sold 30,000 shares of ABIOMED, Inc. (ABMD) in trading session dated Feb. 06, 2019. These shares are worth $10,502,700 and were traded at $350.09 each. The SEC filing shows that Weber David M performed a sale of 24,000 shares. The COO disposed these shares by way of transaction on Jan. 25, 2019. The company’s shares were given away at $351.47 per share worth to an income of some $8,435,280 on account of Weber David M.

VP, Global Sales & Marketing, Howley Michael G, sold 10,000 common shares of ABIOMED, Inc. (ABMD) in the open market. In a transaction dated Sep. 25, 2018, the shares were put up for sale at an average price of $432.5, raking in a sum of $4,325,000. After this sale, 52,992 common shares of ABMD are directly owned by the insider, with total stake valued at $18,807,921.

In the transaction dated Sep. 24, 2018, the great number of shares disposed came courtesy the VP Healthcare Solutions; Greenfield Andrew J disposed a total of 5,000 shares at an average price of $420, amounting to approximately $2,100,000. The insider now directly owns 50,924 shares worth $18,073,946.

ABIOMED, Inc. (ABMD) Analyst Guide

Several analysts have released their opinion on ABIOMED, Inc. (NASDAQ:ABMD), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.45 average brokerage recommendation.